Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Fig. 2

CONSORT for FDRT-002 trial. Arm A, 5 weeks of treatment with radiotherapy 50 Gy/25 fractions with concurrent capecitabine 625 mg/m2 twice daily 5 days per week and oxaliplatin 50 mg/m2 once weekly; Arm B, 5 weeks of treatment with radiotherapy 55 Gy/25 fractions with concurrent capecitabine 625 mg/m2 twice daily 5 days per week and oxaliplatin 50 mg/m2 once weekly, followed by a cycle of XELOX. ITT, intention to treat; TME, total mesorectal excision

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us